Beam Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript

May 30, 2023 / 02:20PM GMT
Dae Gon Ha - Stifel - Analyst

Great. Good morning, everyone, continuing our session on our inaugural virtual genetic medicines' day.

My name is Dae Gon Ha, one of the biotech analysts at Stifel. Joining me for the next half-hour is Beam Therapeutics. And we've got John Evans, CEO of Beam Therapeutics joining us. So John, thank you very much.

John Evans - Beam Therapeutics Inc. - CEO & Director

Great to be here. Thank you.

Questions and Answers:

Dae Gon Ha - Stifel - Analyst

So quick housekeeping. If you, in the audience, have any questions you'd like me to direct to John, please e-mail me at [email protected] or you can just use the chat function (technical difficulty) questions. So John, I knew this happens all the time and I hate to do this, but if you wouldn't mind providing us with an overview of the catalysts and milestones as well as your programs that we should keep an eye out for.

John Evans - Beam Therapeutics Inc. - CEO & Director

Absolutely.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot